Impact Capital Partners LLC acquired a new position in shares of Medtronic plc (NYSE:MDT – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 3,422 shares of the medical technology company’s stock, valued at approximately $273,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. DecisionMap Wealth Management LLC acquired a new stake in Medtronic in the fourth quarter valued at $474,000. PGGM Investments grew its holdings in Medtronic by 9.3% in the fourth quarter. PGGM Investments now owns 1,243,301 shares of the medical technology company’s stock valued at $99,315,000 after purchasing an additional 105,611 shares during the last quarter. Lazard Freres Gestion S.A.S. grew its holdings in Medtronic by 32.1% in the fourth quarter. Lazard Freres Gestion S.A.S. now owns 1,530,933 shares of the medical technology company’s stock valued at $122,290,000 after purchasing an additional 371,742 shares during the last quarter. Achmea Investment Management B.V. grew its holdings in Medtronic by 0.7% in the fourth quarter. Achmea Investment Management B.V. now owns 192,024 shares of the medical technology company’s stock valued at $15,339,000 after purchasing an additional 1,248 shares during the last quarter. Finally, Rakuten Securities Inc. boosted its stake in shares of Medtronic by 753.8% during the fourth quarter. Rakuten Securities Inc. now owns 333 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 294 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.
Insider Activity
In other Medtronic news, EVP Brett A. Wall sold 12,437 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $90.00, for a total transaction of $1,119,330.00. Following the completion of the sale, the executive vice president now owns 40,979 shares in the company, valued at $3,688,110. This trade represents a 23.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.20% of the company’s stock.
Medtronic Stock Performance
Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The medical technology company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.03. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. The company had revenue of $8.29 billion for the quarter, compared to the consensus estimate of $8.33 billion. Equities analysts anticipate that Medtronic plc will post 5.46 earnings per share for the current year.
Medtronic Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, April 11th. Stockholders of record on Friday, March 28th will be paid a $0.70 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.00%. Medtronic’s dividend payout ratio (DPR) is currently 85.11%.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. Robert W. Baird increased their price objective on Medtronic from $90.00 to $91.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Medtronic in a research note on Wednesday, February 19th. Truist Financial decreased their price objective on Medtronic from $93.00 to $89.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Medtronic in a research note on Wednesday, February 19th. Finally, Sanford C. Bernstein increased their target price on Medtronic from $96.00 to $97.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $96.07.
Check Out Our Latest Analysis on MDT
Medtronic Profile
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Recommended Stories
- Five stocks we like better than Medtronic
- How to Invest in Small Cap Stocks
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Pros And Cons Of Monthly Dividend Stocks
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Stock Average Calculator
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.